Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.
Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.
['Tuloup|Vianney|V|', 'France|Mathilde|M|', 'Garreau|Romain|R|', 'Bleyzac|Nathalie|N|', 'Bourguignon|Laurent|L|', 'Tod|Michel|M|', 'Goutelle|Sylvain|S|']
D004347:Drug Interactions D004364:Pharmaceutical Preparations D017828:Rifabutin D012293:Rifampin D012294:Rifamycins
rifampicin rifabutin drug-drug interaction pharmacokinetics